{"id":550,"date":"2017-10-31T10:12:17","date_gmt":"2017-10-31T10:12:17","guid":{"rendered":"http:\/\/www.nemaura.co.uk\/?p=550"},"modified":"2021-11-17T16:23:14","modified_gmt":"2021-11-17T16:23:14","slug":"improved-nsaid-gels-3x-faster-penetration-rates-48-hour-sustained-release-developed-nemaura-pharma","status":"publish","type":"post","link":"https:\/\/nemaura.co.uk\/improved-nsaid-gels-3x-faster-penetration-rates-48-hour-sustained-release-developed-nemaura-pharma\/","title":{"rendered":"Improved NSAID Gels with 3x Faster Penetration Rates and 48 Hour Sustained Release Developed by Nemaura Pharma"},"content":{"rendered":"

LOUGHBOROUGH, England–(BUSINESS WIRE<\/a>)–Sufferers of acute arthritic-related pain using \u2018over the counter\u2019 gels to alleviate muscle ache and joint inflammation may be interested in the results of laboratory trials\u00a0recently\u00a0carried out by Nemaura Pharma.<\/p>\n

The UK-based company has developed two new gels which achieve up to three-times faster drug penetration rate compared with marketed products of the same\u00a0strength and therefore faster onset of action, and up to 48 hours sustained impact from a single application when administered through the skin using Nemaura\u2019s proprietary delivery system Memspatch\u00ae.<\/p>\n

Musculoskeletal pain alleviation and management is crucial for the 10 million people in the UK living with some form of arthritis. According to Arthritis Research UK,\u00a0arthritis\u00a0will cost the economy \u00a33.43 billion in lost working days by 2030,\u00a0with\u00a0the problem set to\u00a0worsen\u00a0as the population ages.<\/p>\n

Nemaura’s\u00a0focus on developing a more efficient and cost-effective pain-relieving system\u00a0has the potential to\u00a0significantly contribute to\u00a0the fast growing non-steroidal anti-inflammatory drug (NSAID)\u00a0global market valued in 2015 at $12bn per year.<\/p>\n

The new gels were developed over a period of\u00a018 months,\u00a0by\u00a0Nemaura\u00a0comparing the efficacy of\u00a0commonly-used NSAIDs\u00a0diclofenac and ibuprofen\u00a0gels\u00a0with\u00a0its\u00a0innovative\u00a0Memspatch\u00ae drug delivery technology.\u00a0Oral and parenteral formats of both these NSAIDs have recognised\u00a0pharmacokinetic drawbacks\u00a0leaving skin based\u00a0drug\u00a0delivery as a\u00a0more attractive\u00a0format. However, age-related thickening of the skin can lead to a poor rate of gel absorption\u00a0and the tendency for some patients to over-medicate.<\/p>\n

The\u00a0Memspatch\u00ae is expected to overcome these limitations given it provides\u00a0for\u00a0a rapid or controlled slow delivery of drug formulations, with users\u00a0requiring\u00a0little training, making\u00a0self-medication easy and relatively pain free.<\/p>\n

Commenting on the study results,\u00a0Nemaura\u00a0CEO\u00a0Dr\u00a0Faz Chowdhury said: \u201cOur goal is to improve the life experience of anyone affected by pain.\u00a0We are excited by our progress, as these\u00a0results bring a new product closer to market. In the past six months we have grown our team of device technologists,\u00a0chemists and\u00a0scientists to\u00a035, and plan for further expansion\u00a0in 2018\u00a0on the back of these promising results.”<\/p>\n

Nemaura\u2019s\u00a0versatile proprietary gel formulations\u00a0and delivery technologies\u00a0can be used with a large number of established medications to\u00a0provide\u00a0either\u00a0a rapid or controlled slow delivery of drug formulations.<\/p>\n

In 2016,\u00a0Nemaura\u00a0received\u00a0the\u00a0Frost & Sullivan\u00a0Global\u00a0recognition of its advanced capability in skin drug delivery.\u00a0With\u00a0patents secured or pending in multiple countries across numerous patent families,\u00a0Nemaura\u00a0aims to be one of the leading pharmaceutical technologists in this fast-growing market, which is expected to be worth \u00a333billion by 2018.<\/p>\n

About Nemaura Pharma<\/strong><\/p>\n

www.nemaura.co.uk<\/a><\/p>\n

Founded in 2005, Nemaura Pharma is a\u00a0private specialist biotech\u00a0company\u00a0focusing on\u00a0cutting-edge\u00a0innovative drug formulation and medical device technologies\u00a0designed\u00a0to radically improve the way drugs are administered through the skin.<\/p>\n

The company has secured\u00a0over\u00a0\u00a325m (over\u00a0<\/strong>$30m) in licensing and development payments, and private investment. In addition,\u00a0Nemaura\u00a0has been awarded five highly competitive British Government grants, and\u00a0the\u00a0Frost & Sullivan 2016 Enabling Technology Leadership Award in Transdermal Drug Delivery, and\u00a0has\u00a0patents secured or pending in multiple countries across\u00a0numerous\u00a0patent families.<\/p>\n

The company employs\u00a0multi-disciplinary teams of\u00a0scientists\u00a0and engineers\u00a0at its headquarters and research facilities in the Advanced Technology Centre on the Loughborough University Science and Enterprise Park (LUSEP) in the United Kingdom.<\/p>\n

Cautionary Statement Regarding Forward-Looking Statements.<\/strong><\/p>\n

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.<\/p>\n","protected":false},"excerpt":{"rendered":"

LOUGHBOROUGH, England–(BUSINESS WIRE)–Sufferers of acute arthritic-related pain using \u2018over the counter\u2019 gels to alleviate muscle ache and joint inflammation may be interested in the results of laboratory trials\u00a0recently\u00a0carried out by Nemaura Pharma. The UK-based company has developed two new gels which achieve up to three-times faster drug penetration rate compared with marketed products of the […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,9,6],"tags":[],"_links":{"self":[{"href":"https:\/\/nemaura.co.uk\/wp-json\/wp\/v2\/posts\/550"}],"collection":[{"href":"https:\/\/nemaura.co.uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nemaura.co.uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nemaura.co.uk\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/nemaura.co.uk\/wp-json\/wp\/v2\/comments?post=550"}],"version-history":[{"count":1,"href":"https:\/\/nemaura.co.uk\/wp-json\/wp\/v2\/posts\/550\/revisions"}],"predecessor-version":[{"id":1146,"href":"https:\/\/nemaura.co.uk\/wp-json\/wp\/v2\/posts\/550\/revisions\/1146"}],"wp:attachment":[{"href":"https:\/\/nemaura.co.uk\/wp-json\/wp\/v2\/media?parent=550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nemaura.co.uk\/wp-json\/wp\/v2\/categories?post=550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nemaura.co.uk\/wp-json\/wp\/v2\/tags?post=550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}